文献速递乳腺癌

局部晚期内分泌反应性乳腺癌绝经前患者接受来曲唑时地加瑞克与曲普瑞林新辅助治疗的随机II期试验

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
PubMed 文献 · J Clin Oncol · 2018-12-27

该随机II期试验纳入51例绝经前、ER/PR>50%、HER2阴性、cT2-4b任何N M0乳腺癌患者,比较地加瑞克与曲普瑞林联合来曲唑新辅助内分泌治疗的卵巢功能抑制(OFS)效果。主要终点为至最佳OFS时间,地加瑞克组中位3天 vs 曲普瑞林组14天(HR 3.05,95%CI 1.65-5.65,P<.001)。地加瑞克组后续周期OFS维持,曲普瑞林组15.4%患者第1周期后OFS不达标。

要点

  • 地加瑞克联合来曲唑至最佳OFS的中位时间3天,曲普瑞林联合来曲唑为14天(HR 3.05,P<.001)。
  • 地加瑞克组所有患者后续周期OFS维持,曲普瑞林组15.4%患者第1周期后OFS不达标。
  • 两组不良事件均符合预期。

核心结论

  • 在接受来曲唑新辅助内分泌治疗的绝经前乳腺癌患者中,地加瑞克较曲普瑞林能更快速地达到OFS并更有效地维持。

研究设计与样本

  • 随机II期试验,2014年2月至2017年1月入组51例绝经前乳腺癌患者,随机接受曲普瑞林3.75 mg肌注每周期第1天(n=26)或地加瑞克240 mg皮下注射第1周期第1天、后80 mg皮下注射第2-6周期第1天(n=25),均联合来曲唑2.5 mg/日共6个28天周期,末次注射后2-3周手术。

主要发现

  • 至最佳OFS时间:地加瑞克联合来曲唑组中位3天 vs 曲普瑞林联合来曲唑组14天(HR 3.05,95%CI 1.65-5.65,P<.001)。
  • 地加瑞克联合来曲唑组所有患者后续周期OFS维持;曲普瑞林联合来曲唑组15.4%患者第1周期后OFS不达标(127次测量中6次事件)。
  • 两组不良事件均符合预期。

关键数值与推荐

  • 最佳OFS定义为中央评估的雌二醇水平≤2.72 pg/mL(≤10 pmol/L)。
  • 主要终点为至最佳OFS时间(从首次注射至新辅助治疗期间首次评估雌二醇≤2.72 pg/mL)。
  • 曲普瑞林剂量3.75 mg肌注每周期第1天;地加瑞克240 mg皮下注射第1周期第1天,后80 mg皮下注射第2-6周期第1天;来曲唑2.5 mg/日。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer. PATIENTS AND METHODS: Premenopausal women with stage cT2 to 4b, any N, M0; estrogen receptor and progesterone receptor greater than 50%; human epidermal growth factor receptor 2-negative breast cancer were randomly assigned to triptorelin 3.75 mg administered intramuscularly on day 1 of every cycle or degarelix 240 mg administered subcutaneously (SC) on day 1 of cycle 1 then 80 mg SC on day 1 of cycles 2 through 6, both with letrozole 2.5 mg/day for six 28-day cycles. Surgery was performed 2 to 3 weeks after the last injection. Serum was collected at baseline, after 24 and 72 hours, at 7 and 14 days, and then before injections on cycles 2 through 6. The primary end point was time to optimal OFS (time from the first injection to first assessment of centrally assessed estradiol level ≤ 2.72 pg/mL [≤ 10 pmol/L] during neoadjuvant therapy). The trial had 90% power to detect a difference using a log-rank test with a two-sided α of .05. Secondary end points included response, tolerability, and patient-reported endocrine symptoms. RESULTS: Between February 2014 and January 2017, 51 patients were enrolled (n = 26 received triptorelin plus letrozole; n = 25 received degarelix plus letrozole). Time to optimal OFS was three times faster for patients assigned to degarelix and letrozole than to triptorelin and letrozole (median, 3 v 14 days; hazard ratio, 3.05; 95% CI, 1.65 to 5.65; P < .001). Furthermore, OFS was maintained during subsequent cycles for all patients assigned to receive degarelix and letrozole, whereas 15.4% of patients assigned to receive triptorelin and letrozole had suboptimal OFS after cycle 1 (six events during 127 measurements). Adverse events as a result of both degarelix plus letrozole and triptorelin plus letrozole were as expected. CONCLUSION: In premenopausal women receiving letrozole for neoadjuvant endocrine therapy, OFS was achieved more quickly and maintained more effectively with degarelix than with triptorelin.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dellapasqua S, Gray KP, Munzone E, et al. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. J Clin Oncol. 2018. PMID: 30589600. doi:10.1200/JCO.18.00296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。